Colcrys is indicated for the prophylaxis and treatment of acute gout flares in adults and the treatment of familial Mediterranean fever (FMF) in adults and children aged four years or older. Colcrys is part of Takeda’s gout treatment portfolio and was launched commercially in the US in 2009. Gout affects an estimated 8.3 million Americans.

Colchicine tablets will be marketed under the Prasco label and will be the only colchicine product on the market that is therapeutically equivalent and automatically substitutable for prescriptions written for Colcrys.

The gout treatment recently came under scrutiny due to huge price increases, which came about reportedly as a result of US FDA’s 2006 Unapproved Drugs initiative [1].

The partnership ‘will help enhance patient access to an important gout medicine by supplying Prasco with Colchicine Tablets, USP, manufactured under the same rigorous standards and processes as Colcrys’, according to Mr Douglas Cole, President, Takeda Pharmaceuticals USA.

Related articles
Authorized generics reduce drug prices

Authorised generics implicated in pay-to-delay deals

Reference
1.   GaBI Online - Generics and Biosimilars Initiative. Another old drug to see huge price increase in US [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Jan 23]. Available from: www.gabionline.net/Policies-Legislation/Another-old-drug-to-see-huge-price-increase-in-US

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro PharmaCommunications International. All Rights Reserved.